Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 7/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4056104 | 0.90 | SLC6A2 (0.53) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4053135 | 0.84 | SLC6A2 (0.40) | SLC6A2SLC6A3KDM4ESLC6A4 | |
| SCHEMBL4058532 | 0.84 | SLC6A2 (0.42) | SLC6A2SLC6A3KDM4ESLC6A4L3MBTL1 | |
| SCHEMBL4064710 | 0.81 | SLC6A2 (0.40) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4062000 | 0.80 | KDM4E (0.38) | SLC6A2SLC6A3KDM4ESLC6A4L3MBTL1 | |
| SCHEMBL4056113 | 0.80 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4KMT2A | |
| SCHEMBL4065783 | 0.79 | SLC6A2 (0.56) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4055078 | 0.79 | SLC6A2 (0.35) | SLC6A2SLC6A3KDM4ESLC6A4L3MBTL1 | |
| Hydrochloric Acid SCHEMBL4947369 | 0.78 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4 | |
| SCHEMBL4053312 | 0.77 | SLC6A2 (0.55) | SLC6A2SLC6A3SLC6A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2061776-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | Wyeth a Corporation of the State of Delaware (US) | 2009-05-27 | — | — | EP | disclosed |
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-07-03 | — | — | US | disclosed |
| WO-2008073459-A1 | ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161366-A1 | AMINOALKYL SUBSTITUTED ARYL SULFAMIDE DERIVATIVES AND METHODS OF THEIR USE | SLC6A4, SLC6A2, SLC6A3 | SLC6A2 2/4885SLC6A3 3/4885KDM4E 3015/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.